The Satellite Symposium will be chaired by Prof.
The focus of the symposium will be on the continued need for innovative drugs in ulcerative colitis as well as the novel mechanism of action and clinical data from the Phase 2a induction and maintenance studies with ABX464.
About ABX464
ABX464 is a highly differentiated oral drug candidate, with a novel mechanism of action based on the upregulation of a single microRNA (miRNA-124) with potent anti-inflammatory properties. ABX464 was shown to exert its anti-inflammatory effects through binding to the cap binding complex (CBC), which sits at the 5' end of every RNA molecule in the cell. By binding to the CBC, ABX464 reinforces the biological functions of CBC in cellular RNA biogenesis. Specifically, ABX464 enhances the selective splicing of a single long non-coding RNA to generate the anti-inflammatory microRNA, miRNA-124, which downregulates pro-inflammatory cytokines and chemokines like TNF-, IL-6 and MCP-1, thereby 'putting a brake' on inflammation and suggesting broad potential as a novel anti-inflammatory therapeutic agent. A seven- to ten-fold increase in miRNA-124 levels was observed in colorectal biopsies of UC patients treated with ABX464. ABX464 does not impact the splicing of cellular genes. In addition to the ongoing Phase 2b trial in UC, ABX464 is also being investigated in a Phase 2a trial in rheumatoid arthritis and soon in a Phase 2b trial in Crohn's disease, where its effects could have significant potential.
About
Contact:
Tel: +33 6 24 50 69 63
Email: regina.jehle@abivax.com
(C) 2020 Electronic News Publishing, source